April 13, 2009
Phase III Data for Gilead Sciences' Darusentan Accepted as Late-Breaker Presentation at ASH 2009
The abstract titled, “Fixed Doses of Darusentan Compared to Placebo in
Treatment Resistant Hypertension” (Presentation# LB-OR-06), will be
Darusentan is a propanoic-acid class endothelin receptor antagonist (ERA) being investigated in clinical trials as an add-on oral therapy for patients with resistant hypertension. Darusentan selectively blocks the endothelin type-A (ETA) receptor, which if activated by endothelin-1 (ET-1), leads to vasoconstriction (narrowing of blood vessels) and cell proliferation. Elevated ET-1 blood concentrations have been reported in some patients with hypertension, including several subgroups of hypertensive patients that have been historically difficult to treat.
Darusentan is an investigational compound and has not yet been determined safe or efficacious in humans.
This press release includes forward-looking statements, within the
meaning of the Private Securities Litigation Reform Act of 1995, that
are subject to risks, uncertainties and other factors, including the
risk that the safety and efficacy data obtained from the DAR-311
(DORADO) clinical trial will not be observed in other clinical trials.
In addition, feedback from regulatory authorities or results from
clinical trials might result in delays or require additional trials to
be performed. As a result, we may cease development of darusentan for
the treatment of resistant hypertension. These risks and uncertainties
could cause actual results to differ materially from those referred to
in the forward-looking statements. Risks are described in detail in the
Gilead Annual Report on Form 10-K for the year ended
For more information on Gilead, please call the
Gilead Sciences, Inc.
Susan Hubbard, 650-522-5715 (Investors)
Nathan Kaiser, 650-522-1853 (Media)